Aiosyn, a medical software company specialising in AI-powered pathology solutions, has released its first AI algorithm in its Mitosis product family: Aiosyn Mitosis Research. The innovative deep-learning algorithm is designed to automatically scan for cells undergoing division to assist research pathology laboratories with mitotic figure detection in whole-slide images from cancer biopsies and resections.
The second algorithm in the family, Aiosyn Mitosis Breast for diagnostic use, is currently undergoing clinical validation.
"We are thrilled to introduce Aiosyn Mitosis Research, an AI-powered mitosis detection solution that will support cancer researchers with an innovative AI-based computational biomarker approach that improves the efficiency and consistency of results." says Patrick de Boer, CEO of Aiosyn.
Counting mitotic figures in histological slide preparations is a tedious and subjective task with poor reproducibility. The AI-powered mitosis detection solution empowers laboratories to implement a more consistent and efficient protocol for biomarker discovery and drug development studies, thereby improving the quality and standardisation of results. By effectively highlighting mitotic figures in haematoxylin and eosin (H&E) slides before cases are opened for review, Aiosyn’s algorithm significantly enhances the efficiency of mitosis analysis, a critical biomarker for tumour growth evaluation.
In the illustration above, cells undergoing division are identified and highlighted with Aiosyn's algorithm for automated mitosis detection.
Aiosyn Mitosis Research is a modular and flexible software offered as a service solution that can be integrated into existing digital pathology software. It can be deployed through the cloud or on-premise installation, adapting to different laboratory setups. This release marks yet another significant milestone for Aiosyn, following the successful launch of AiosynQC, an automated quality control (QC) tool that significantly streamlines the digital pathology workflow.
Aiosyn is currently in the validation phase for another product in the Mitosis product family, Aiosyn Mitosis Breast, for clinical diagnostics. Aiosyn Mitosis Research and Aiosyn Mitosis Breast will be part of a portfolio of deep learning algorithms currently in development for different pathologies for which there is a clear need to improve diagnostic precision and quality.
Aiosyn is a Dutch medical software company that develops AI-powered pathology solutions that are integrated into standard pathology workflows. The Aiosyn team has been built upon over 20 years of research experience in the field of pathology and is rooted into the pathology practice.
